These data further suggests that high CDK4 selectivity drives improved safety and tolerability, enabling continuous dosing, excellent adherence, and potentially greater efficacy. Grade 3 or high in neutropenia was numerically lower with the thermocyclip than with any of the approved agents, with no grade four or five neutropenia reported. Any grade diarrhea was lower than with Abemocyclip and comparable to pulvocyclip and ribocyclip. Dose reductions due to adverse events were 14% with a thermocyclip compared to 32 to 43% with the approved agent. Turning to tuber, we are advancing an extensive program for this potentially best in class PD1 VGF bisecific antibody with over 1,200 patients treated globally and a consistent safety profile. This includes two ongoing phase three trials with two additional phase three trials expected to begin this year. Updated results at ESMO strengthen our confidence as we expand Tibonatomics development. Since SITC25, confirmed response rate for the pivotal dose of Tibonatomic plus doublet chemotherapy from the ongoing phase two study have risen by roughly 20 percentage points in non-squamous and squamous first-line non-small cell lung cancer. They now stand at approximately 80%, exceeding those of Tesla lismap plus chemotherapy in this study. Medium progressive free survival was nearly 14 months for both histologies, an improvement of roughly four to five months versus the comparators. Notably, Tesla lisimap's efficacy was consistent consistent with historical phase three results for the leading PD1 antibody pembry map, which supports the relevance of the control arms. We are also encouraged by how Tvanatomic efficacy and safety results compare with phase three data for the PD1 VGF bispecific antibody ivanisomap, while recognizing the limitations of crosstrial comparisons. Now for INI, Tilrechomic, a potential first-in-class trispecific antibody, Tilrechomic was designed in-house to simultaneously target multiple complementary drivers of type 2 inflammation, IL-4, IL-13, and TSLP. Phase 2 results and atopic derivatitis provide compelling proof of concept. At the top monthly doses, Tilrechomic treatment led to placebo jazzid response rate of about 50% for EZ75 to find a 75% or greater improvement in the eczema area and severity index. While cross-trial comparisons have limitations, these phase two data suggest the potential for superiority over dupilomap, the current standard of care biologic. These secondary endpoints in our ongoing phase three program are powered to test this hypothesis in a head to head setting. For safety, Torrecomeg demonstrated a favorable profile at subcutaneous doses up to 400 milligrams once every four weeks, the observed frequency of conjunctivitis and injection site reactions were lower than rates reported with Dupillomap and comparable to placebo. Beyond aterpic dermatitis, Telrechomic offers a pipeline and a product opportunity, targeting pathways that are validated by approved therapies across nine different diseases. Late stage studies are underway in severe asthma and moderate to severe COPD. Moving to our potential best in class pneumococcal conjugate vaccine program, building on PREFNAS 25 plus year legacy of effectiveness and safety, we're advancing next generation candidates designed for leading serotype and invasive disease coverage. In pediatrics, PCB 25 delivered strong phase two results. All 20 serotypes shared with PREFNA 20 met the twofold post-dose post-dose 4 IgG criterion historically used to establish non-inferiority. Since the pediatric licensure of PREFNA 20 in 2023, the FA established an updated, more stringent, 1.5-fold non-inferiority criterion that is incorporated into our phase three design. Given the phase two results and tighter confidence intervals expected with a much larger sample size in phase three, modeling predicts this criterion will be met for at least 22 of 25 serotypes in our pivotal study. Taken together with serial response data, functional OPA T test, and the totality of evidence approach to licensure. These results provide confidence as we aim to deliver a best in class pediatric pneumococcal vaccine protecting against stereotypes that collectively cause an estimated 84% of invasive disease cases in US children under five. This would represent an incremental increase of approximately 25 percentage points versus PREFNA 20. Our phase three program is well underway with the phase three lot to lot consistently consistency study already fully enrolled. In adults, PCB 35 extends the enhanced serotype 3 technology we validate it with PCB 25 to other key serotypes with a phase one start expected this year. Looking ahead, we expect a strong cadence of regulatory decisions, data readouts, and pivotal study starts over the next 12 months. These include a readout from MEFRA 1, which, based on the current event rate is now expected in the first quarter of 2027. If successful, MEFRO 1 could support approval for MEPROMETAS, our in-house discovered potential first in class EZH2 inhibitor for prostate cancer, expanding our franchise. With that, I'll hand it back to Albert.
Passages & reports (19) 26:15 These data further suggests that high CDK4 selectivity drives improved safety and tolerabi… Report 26:35 Any grade diarrhea was lower than with Abemocyclip and comparable to pulvocyclip and riboc… Report 26:55 we are advancing an extensive program for this potentially best in class PD1 VGF bisecific… Report 27:14 begin this year. Updated results at ESMO strengthen our confidence as we expand Tibonatomi… Report 27:34 non-squamous and squamous first-line non-small cell lung cancer. They now stand at approxi… Report 27:54 comparators. Notably, Tesla lisimap's efficacy was consistent consistent with historical p… Report 28:14 for the PD1 VGF bispecific antibody ivanisomap, while recognizing the limitations of cross… Report 28:34 inflammation, IL-4, IL-13, and TSLP. Phase 2 results and atopic derivatitis provide compel… Report 28:54 severity index. While cross-trial comparisons have limitations, these phase two data sugge… Report 29:14 safety, Torrecomeg demonstrated a favorable profile at subcutaneous doses up to 400 millig… Report 29:34 Telrechomic offers a pipeline and a product opportunity, targeting pathways that are valid… Report 29:54 PREFNAS 25 plus year legacy of effectiveness and safety, we're advancing next generation c… Report 30:14 twofold post-dose post-dose 4 IgG criterion historically used to establish non-inferiority… Report 30:33 incorporated into our phase three design. Given the phase two results and tighter confiden… Report 30:53 data, functional OPA T test, and the totality of evidence approach to licensure. These res… Report 31:13 US children under five. This would represent an incremental increase of approximately 25 p… Report 31:32 adults, PCB 35 extends the enhanced serotype 3 technology we validate it with PCB 25 to ot… Report 31:52 pivotal study starts over the next 12 months. These include a readout from MEFRA 1, which,… Report 32:12 first in class EZH2 inhibitor for prostate cancer, expanding our franchise. With that, I'l… Report